Condiciones de salud que ácido fólico puede ayudar a apoyar.
Folic acid deficiency is a primary, well-established cause of megaloblastic macrocytic anemia, resulting from impaired DNA synthesis and disrupted red blood cell maturation in bone marrow. Folic acid has FDA approval for treating megaloblastic and macrocytic anemias due to folate deficiency. An umbrella review of intervention trials demonstrated a relative risk of 0.21 (95% CI: 0.11–0.38) for megaloblastic anemia with folic acid supplementation during pregnancy. Correct identification of folate versus B12 deficiency before supplementation is clinically essential, as folic acid can mask the hematological signs of B12 deficiency.
Folic acid (vitamin B9) reduces plasma homocysteine, a risk factor for arterial endothelial damage and accelerated atherosclerosis. A 2022 network meta-analysis specifically included folic acid among vitamins assessed for arterial stiffness reduction via PWV. Hyperhomocysteinemia impairs endothelial function and accelerates vascular disease; folic acid supplementation normalizes homocysteine and improves FMD.
Multiple RCTs and meta-analyses have examined folic acid supplementation's effect on blood pressure, with consistently mixed but statistically significant results depending on dose and population. A large meta-analysis of 22 RCTs (n=41,633) showed folic acid supplementation significantly decreased systolic blood pressure (WMD: −1.10 mmHg; 95% CI: −1.93 to −0.28). Effects appear more pronounced in hypertensive patients with concurrent hyperhomocysteinemia and when doses of at least 5,000 µg/day are used. The primary mechanism proposed is improvement of endothelial function and reduction of plasma homocysteine.
Folate is naturally present in breast milk and is the primary folate source for exclusively breastfed infants. WHO and MotherToBaby recommend 500 µg/day of folic acid during lactation. Maternal supplementation at typical doses does not substantially alter total milk folate in well-nourished women, but can prevent a postpartum decline in milk folate concentration and leads to the appearance of unmetabolized folic acid in milk. Folate needs during lactation are increased due to its role in DNA, RNA, and protein biosynthesis.
Folic acid (vitamin B9) deficiency is associated with recurrent aphthous stomatitis (RAS), with multiple observational studies finding lower dietary folate intake in RAS patients compared to controls. StatPearls (NCBI Bookshelf) confirms hematinic deficiencies including folic acid occur twice as often in RAS patients. Supplementation with folic acid has been shown in small clinical trials and prescribed clinically to reduce frequency and severity of canker sores, particularly in deficient individuals.
Folate (folic acid) deficiency is one of the most common and persistent nutritional deficiencies in celiac disease, arising from malabsorption in the proximal small intestine, and may persist on long-term GFD. The 2013 ACG guidelines list folic acid among the first micronutrients to screen and supplement at diagnosis. A 2002 study by Hallert et al. demonstrated poor folate status persisting in coeliac patients after 10 years on GFD.
Low folate is consistently associated with elevated cervical dysplasia risk and HPV infection prevalence. An early RCT in OC users found significant improvement in CIN biopsy and cytology scores with 10 mg/day folic acid vs. placebo. However, two larger definitive RCTs (235–331 women, 5–10 mg/day) found no significant regression of established CIN, leading to the conclusion that folate is a cofactor in CIN initiation rather than a therapeutic agent for established disease.
Folic acid is the synthetic oxidized form of folate used in children's MVMs due to its stability and high bioavailability. It is present in virtually all children's MVMs per NIH ODS-funded label surveys, with data showing most products contain it at or above the pediatric RDA. It is the predominant form of vitamin B9 in commercial pediatric multivitamins.
Serum and CSF folate concentrations decline with age, while homocysteine rises, and low folate status is associated with mild cognitive impairment and dementia in population-based studies. Folic acid supplementation reduces plasma homocysteine and inflammatory markers in older adults, and a systematic review found positive effects on cognitive function in elderly individuals with mild cognitive impairment. However, consistent evidence that supplementation improves cognition or slows decline in cognitively healthy older adults is lacking.
Folic acid (vitamin B9) deficiency is common in Crohn's disease due to malabsorption and interference by medications including sulfasalazine and methotrexate. A PubMed study found serum folate significantly lower in CD patients than controls. Supplementation is recommended by gastroenterology authorities to support cell growth, reduce inflammatory homocysteine, and lower colorectal cancer risk.
Folate deficiency is consistently associated with depression, and folic acid supplementation has been studied as both a monotherapy and adjunct. Multiple clinical trials and a WFSBP/CANMAT 2022 guideline review found evidence supporting folic acid as an adjunct for MDD. MTHFR gene variants that impair folate metabolism are associated with antidepressant non-response.
Folic acid is essential for DNA synthesis and repair during spermatogenesis. Subfertile men with low folate show increased sperm DNA fragmentation. Combined zinc+folic acid supplementation improved sperm concentration in some RCTs. However, a large NIH-funded RCT (n=2,370) found no improvement in live birth rates with combined zinc+folic acid vs. placebo, indicating benefits may be limited to folate-deficient men.
Folic acid (vitamin B9) is the most firmly established periconception supplement. Higher folate intake is associated with lower risk of anovulation and ovulatory infertility, shorter time to pregnancy, and greater success with infertility treatment. US and global guidelines recommend 400–800 mcg/day for all women of reproductive age.
Folic acid has been studied as a potential xanthine oxidase inhibitor and uric acid-lowering agent. A 2022 animal study found folic acid intervention observably reduced uric acid and downregulated xanthine oxidase and adenosine deaminase activities in hyperuricemic rats. A pilot combination clinical trial including folic acid in chronic gout patients demonstrated reduced plasma uric acid and symptoms.
Folic acid is the synthetic form of folate (vitamin B9), essential for DNA methylation, nucleotide synthesis, and homocysteine metabolism. In aging, folate deficiency accelerates epigenetic drift, cognitive decline, and cardiovascular risk. The VITACOG RCT demonstrated combined B-vitamin (including folic acid) supplementation reduces brain atrophy rate by >50% in older adults with elevated homocysteine.
Folic acid (the synthetic form of folate/vitamin B9) is essential for DNA synthesis and cell division, making it critical during periods of rapid growth in pregnancy, infancy, and childhood. The CDC and WHO recognize folic acid as the only form shown to prevent neural tube defects (serious birth defects of the brain, spinal cord, and skull) when taken before and during early pregnancy. Insufficient folate during childhood is associated with stunted growth, megaloblastic anemia, and impaired neurodevelopment.
Folic acid is scientifically linked to cardiovascular health primarily through its role in lowering homocysteine, an amino acid associated with increased CVD risk. Multiple RCT meta-analyses confirm a modest but significant reduction in stroke risk (~10–15%) and a small reduction in overall CVD risk, though benefits for coronary heart disease and mortality are not established. The NIH ODS notes that while folic acid lowers homocysteine, it does not directly decrease the risk of heart disease itself. Benefits appear most pronounced in populations with low baseline folate levels and without preexisting CVD.
Folic acid is the most potent single nutrient for lowering plasma homocysteine, reducing levels by up to 25% in numerous RCTs. It acts as the primary methyl donor in the remethylation of homocysteine to methionine via the MTHFR enzyme. The HOPE-2 trial (n=5522) demonstrated a 2.4 µmol/L reduction in plasma homocysteine with folic acid plus B vitamins. US mandatory fortification since 1998 has demonstrably lowered population homocysteine levels.
Folic acid (vitamin B9) is essential for DNA synthesis in red blood cell precursors. Deficiency causes megaloblastic anemia with fatigue as the primary symptom. Supplementation corrects deficiency-related anemia and resolves fatigue in deficient individuals.
Folic acid (vitamin B9) participates in one-carbon metabolism, DNA methylation, and homocysteine regulation critical for neuronal function. A large 3-year RCT (n=819, 800 µg/day) found folic acid supplementation significantly improved memory, processing speed, and sensorimotor speed in adults aged 50–70 with elevated homocysteine. Evidence is strongest in populations with elevated homocysteine or borderline deficiency.
Folic acid is the synthetic oxidized form of folate used in supplements and food fortification. It requires enzymatic conversion to active 5-MTHF to participate in the methylation cycle. Widely shown to lower homocysteine and support methylation pathway function across numerous RCTs; standard form in public health folate programs worldwide.
Folic acid is an essential B vitamin (B9) critical for nervous system development and maintenance, particularly for DNA synthesis and methylation reactions supporting neurotransmitter production. Deficiency causes neural tube defects and is associated with neurological symptoms and elevated homocysteine damaging nerve tissue.
Folate, in its active form as l-methylfolate, crosses the blood-brain barrier and is required for the enzymatic synthesis of serotonin, dopamine, and norepinephrine. Low folate status has been associated with depleted cerebrospinal fluid serotonin and mood disturbances in clinical and population-based studies. However, folic acid supplementation at physiological doses in already-replete healthy individuals does not consistently improve neurotransmitter-related outcomes or mood. The relationship is most clinically relevant in folate-deficient populations and those with MTHFR polymorphisms that impair conversion of folic acid to active l-methylfolate.
Folate (folic acid) reduces plasma homocysteine, elevated levels of which impair collagen crosslinking in bone matrix and are independently associated with increased fracture risk. Combined B-vitamin supplementation (including folic acid, B12, B6) has been shown in Japanese clinical trials to reduce fracture risk. Folate inadequacy is common in the elderly and represents a modifiable bone health risk.
Folic acid supplementation has been studied in PCOS, showing reductions in BMI particularly in patients with elevated homocysteine levels. It is included among evidence-based vitamins recommended in major PCOS supplement reviews, and elevated homocysteine—reduced by folate—is a recognized cardiovascular risk factor in PCOS.
Folic acid (folate/vitamin B9) is documented as deficient in picky eating children in clinical trials. A 6-month RCT of oral nutritional supplementation in picky eaters showed significant reduction in folate intake inadequacy in the supplemented group. Folate is essential for cell division and DNA synthesis.
Folate (folic acid / 5-methyltetrahydrofolate) is essential for DNA synthesis in rapidly proliferating immune cells and for red blood cell production during post-illness anemia recovery. Deficiency impairs immune reconstitution and is common in post-illness states with reduced food intake.
Folic acid remains important postpartum for red blood cell production, DNA synthesis and tissue repair; it is also transferred to infants via breastmilk. A 2025 PMC systematic review confirmed folic acid (400–800 µg/d) reduces maternal anaemia risk by 30–50%. Postpartum women have been shown to meet only 39% of their folate requirements from food alone.
Folic acid is the most established prenatal nutrient, with strong evidence from RCTs and observational studies showing periconceptional supplementation (400–800 µg/day) reduces neural tube defect (NTD) risk by more than 70%. The NIH ODS, WHO, ACOG, and NICE all recommend routine supplementation before and during early pregnancy. It also reduces megaloblastic anemia risk and may lower preeclampsia and preterm birth risk.
Folic acid is essential in RA management primarily as a supplement prescribed alongside methotrexate (the anchor DMARD for RA) to reduce methotrexate-induced toxicity including mucositis, hepatotoxicity, and gastrointestinal side effects. It is listed by EBSCO as a proposed natural treatment for RA.
Folic acid (vitamin B9) is critical for DNA synthesis and rapid cell division in the hair matrix. Deficiency has been associated with hair loss and has been linked to androgenetic alopecia in systematic reviews. However, isolated RCT evidence for folic acid supplementation in hair loss is lacking, and clinical guidelines cite inadequate data for routine supplementation.
Volver